Literature DB >> 15056599

Antipsychotics and diabetes: review of non-prospective data.

Peter M Haddad1.   

Abstract

BACKGROUND: Much of the existing data regarding the relationship between antipsychotic medications and diabetes mellitus are non-prospective. AIMS: To review critically non-prospective studies examining antipsychotic medications as risk factors for diabetes mellitus.
METHOD: Database and manual searches.
RESULTS: Anecdotal reports indicate that conventional and atypical antipsychotics can cause diabetes mellitus. However, retrospective studies cannot reliably quantify this association, as they do not adequately control for confounding risk factors for diabetes, or for variation in detection and diagnosis of this illness. Most studies report a higher rate of diabetes in patients who use antipsychotic medication than in non-users, and in patients taking atypical v. conventional antipsychotics. Studies assessing the relative risks of diabetes between individual atypical antipsychotics are contradictory.
CONCLUSIONS: Retrospective data are of limited value. Well-designed prospective studies, which account for potential confounders, are needed to investigate the true association between antipsychotic medications and diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056599     DOI: 10.1192/bjp.184.47.s80

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  14 in total

Review 1.  Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

Authors:  R I G Holt; R C Peveler
Journal:  Diabetologia       Date:  2006-05-13       Impact factor: 10.122

2.  Pharmacological interventions for those who have sexually offended or are at risk of offending.

Authors:  Omer Khan; Michael Ferriter; Nick Huband; Nadja Smailagic
Journal:  Cochrane Database Syst Rev       Date:  2009

Review 3.  Pharmacological interventions for those who have sexually offended or are at risk of offending.

Authors:  Omer Khan; Michael Ferriter; Nick Huband; Melanie J Powney; Jane A Dennis; Conor Duggan
Journal:  Cochrane Database Syst Rev       Date:  2015-02-18

4.  Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: a link to impaired glucose metabolism?

Authors:  Veit Roessner; Annette Weber; Andreas Becker; Georg Beck; Helge Frieling; Stefan Bleich
Journal:  Eur J Clin Pharmacol       Date:  2007-02-28       Impact factor: 2.953

5.  Once-monthly paliperidone injection for the treatment of schizophrenia.

Authors:  Delia Bishara
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

6.  Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.

Authors:  Marilyn Ader; W Timothy Garvey; Lawrence S Phillips; Charles B Nemeroff; Georges Gharabawi; Ramy Mahmoud; Andrew Greenspan; Sally A Berry; Dominique L Musselman; Jacqueline Morein; Young Zhu; Lian Mao; Richard N Bergman
Journal:  J Psychiatr Res       Date:  2008-02-25       Impact factor: 4.791

7.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

Review 8.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis.

Authors:  Debra L Foley; Andrew Mackinnon; Vera A Morgan; Gerald F Watts; John J McGrath; David J Castle; Anna Waterreus; Cherrie A Galletly
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

Review 10.  Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.